INTRAVENOUS TREOSULFAN VERSUS INTRAVENOUS TREOSULFAN PLUS CISPLATINUM IN ADVANCED OVARIAN-CARCINOMA

被引：31

作者：

MASDING, J

SARKAR, TK

WHITE, WF

BARLEY, VL

CHAWLA, SL

BOESEN, E

ROSTOM, AY

MENDAY, AP

机构：

[1] LEO LABS LTD,DEPT MED,LONGWICK RD,PRINCES RISBOROUGH,AYLESBURY HP17 9RR,BUCKS,ENGLAND

[2] KING EDWARD VII HOSP,MIDHURST,W SUSSEX,ENGLAND

[3] ABERDEEN ROYAL INFIRM,ABERDEEN AB9 2ZB,SCOTLAND

[4] ST LUKES HOSP,REG CTR RADIOTHERAPY & ONCOL,GUILDFORD,SURREY,ENGLAND

[5] BRISTOL ROYAL INFIRM & GEN HOSP,BRISTOL BS2 8HW,AVON,ENGLAND

[6] S CLEVELAND HOSP,MIDDLESBROUGH TS4 3BW,ENGLAND

[7] ROYAL FREE HOSP,LONDON NW3 2QG,ENGLAND

来源：

BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY | 1990年 / 97卷 / 04期

关键词：

D O I：

10.1111/j.1471-0528.1990.tb01813.x

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Summary. In a prospective, multicentre, randomized trial, the efficacy and tolerance of treosulfan alone was compared with that of treosulfan plus cisplatinum in 135 women with advanced ovarian carcinoma. No statistically significant difference was found between the two treatments in terms of median survival. Combined treatment was associated with significantly greater side‐effects and haematological toxicity. Optimal survival with minimal toxicity can be achieved by using treosulfan alone in patients (mainly stages Ic or II) with minimal postoperative residual disease. Patients (likely to be stage III or IV) with greater residual disease should receive treosulfan plus cisplatinum. Copyright © 1990, Wiley Blackwell. All rights reserved

引用

页码：342 / 351

页数：10

共 16 条

[1]

ABDULLA U, 1983, 13TH P INT C CHEM VI

[2] PRESENT OPTIMAL THERAPY IN OVARIAN-CANCER [J].